Quality indicators for colorectal cancer surgery and care according to patient-, tumor-, and hospital-related factors by Simone Mathoulin-Pélissier et al.
Mathoulin-Pélissier et al. BMC Cancer 2012, 12:297
http://www.biomedcentral.com/1471-2407/12/297RESEARCH ARTICLE Open AccessQuality indicators for colorectal cancer surgery
and care according to patient-, tumor-, and
hospital-related factors
Simone Mathoulin-Pélissier1,2,3*, Yves Bécouarn4, Geneviève Belleannée5, Elodie Pinon6, Anne Jaffré1,
Gaëlle Coureau2,3,7, Dominique Auby8, Jean-Louis Renaud-Salis6, Eric Rullier3,9
Group for Colorectal cancer (GRACCOR)
for the Regional AquitaineAbstract
Background: Colorectal cancer (CRC) care has improved considerably, particularly since the implementation of a
quality of care program centered on national evidence-based guidelines. Formal quality assessment is however still
needed. The aim of this research was to identify factors associated with practice variation in CRC patient care.
Methods: CRC patients identified from all cancer centers in South-West France were included. We investigated
variations in practices (from diagnosis to surgery), and compliance with recommended guidelines for colon and
rectal cancer. We identified factors associated with three colon cancer practice variations potentially linked to better
survival: examination of ≥12 lymph nodes (LN), non-use and use of adjuvant chemotherapy for stage II and stage III
patients, respectively.
Results: We included 1,206 patients, 825 (68%) with colon and 381 (32%) with rectal cancer, from 53 hospitals.
Compliance was high for resection, pathology report, LN examination, and chemotherapy use for stage III patients.
In colon cancer, 26% of stage II patients received adjuvant chemotherapy and 71% of stage III patients. 84% of
stage US T3T4 rectal cancer patients received pre-operative radiotherapy. In colon cancer, factors associated with
examination of ≥12 LNs were: lower ECOG score, advanced stage and larger hospital volume; factors negatively
associated were: left sided tumor location and one hospital district. Use of chemotherapy in stage II patients was
associated with younger age, advanced stage, emergency setting and care structure (private and location); whereas
under-use in stage III patients was associated with advanced age, presence of comorbidities and private hospitals.
Conclusions: Although some changes in practices may have occurred since this observational study, these findings
represent the most recent report on practices in CRC in this region, and offer a useful methodological approach for
assessing quality of care. Guideline compliance was high, although some organizational factors such as hospital size
or location influence practice variation. These factors should be the focus of any future guideline implementation.
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The contrast between increasing colorectal cancer (CRC)
incidence, which has increased by 50% in France between
1980-2000, and stable mortality can be attributed both to
population ageing and to better survival, thanks to
improved treatment for CRC [1]. Increasing numbers of
patients are able to be resected for cure, diagnoses are
made at earlier stages, operative mortality is decreasing
and effective adjuvant treatments for patients stage III at
diagnosis are now available. However, much variation
exists in the way CRC is managed both internationally
[2,3], and nationally within France [4-6], due partly to spe-
cific treatment modalities and their conformity to guide-
lines, and to structural factors such as accessibility, or to
doctors’ willingness and competencies [7].
By reducing unwarranted variations in practice, guide-
lines should lead to better care, fewer inappropriate
interventions and reduced costs [8]. However, active im-
plementation is needed to increase adherence as publica-
tion and dissemination is not sufficient [9]. In France, as
in other European countries, a national cancer plan has
been implemented and adherence is promoted as an im-
portant step to enhancing quality of cancer care [10].
Regional cancer organizations (networks and local care
units) have also been established to facilitate guideline
use and to promote a multidisciplinary approach These
procedural improvements have been put into practice in
specialized centers progressively, but their impact has
not yet been measured and no quality assessment data is
available. Moreover, in the French health care system,
CRC management is decentralized which can be
expected to result in a multiplicity of treatment settings
and specialist practices.
The aim of this article is to investigate and describe
patterns of care management among a prospective co-
hort of primary CRC patients, just after implementation
of regional clinical guidelines. We examine differences
across patient-, tumor- and hospital-related factors using
27 criteria (11 for colon and 16 for rectal cancer) to de-
scribe the quality of colorectal cancer care. We also use
statistical models to investigate factors linked to three
specific quality indicators identified by the National
Quality Forum/American College of Surgeons/Commis-
sion on Cancer and National Comprehensive Cancer
Network (NCCN)/American Society of Clinical Oncol-
ogy [11] and potentially linked to better survival: exam-
ination of ≥12 lymph nodes (LN) [12,13], use of
adjuvant chemotherapy for stage II patients [14] and
non-use for stage III patients [15].
Methods
Background
The Aquitaine region (South-West France) covers ap-
proximately 3 million inhabitants (5% of Frenchpopulation), including over 2,000 incident CRC cases.
Based on national evidence-based guidelines for CRC
management, a multidisciplinary group (38 physicians)
implemented regional guidelines in 2003. Through regu-
lar meetings, and discussion, this group developed po-
tential criteria to assess CRC care quality at four
consecutive stages of patient care: diagnosis and pre-
operative work-up (10 criteria); surgery and pathological
report (10 criteria); non-surgical treatments (4 criteria)
and multidisciplinary team approach (3 criteria). (See
Additional file 1: Appendix A). To disseminate the
guidelines, we sent a global report (including recom-
mendations and criteria) to the 10 local cancer units and
the regional multidisciplinary team (150 practitioners).
In addition, a guideline summary was sent to all regis-
tered regional physicians (about 6,000 general and spe-
cialist practitioners).
Study population and data collection
All patients presenting at local cancer units with primary
invasive colon or rectal cancer during the first year after
guideline implementation (June 2003-June 2004) were
included in this study. Patients were included prospect-
ively and data were collected retrospectively. Cases were
identified by surgeons, pathologists, or referring practi-
tioners, or at multidisciplinary team meetings involving
all 10 local cancer units.
Information was collected from patient medical files
and pathology reports. This included demographic data
(age, gender, place of residence), general status (ECOG
score and comorbid conditions), clinical and surgical
features of primary cancer (familial antecedents,
localization, emergency or scheduled surgery, interven-
tions, complications), diagnostic assessment (colonos-
copy and biopsy, other exams), histological features of
the tumor (histology, number of nodes examined, mar-
gin involvement, tumor stage), preoperative work-up
(abdominal ultrasonography (US), thoracic chest X-ray,
abdominal and thoracic computed tomography), surgical
and adjuvant treatment (chemotherapy and radiother-
apy), and multidisciplinary approach. Staging was based
on the pathological report, and cancer extension was
defined according to TNM classification as stage I
(T1T2N0M0), stage II (T3T4N0M0) stage III (all T
N1N2M0) and stage IV (all T, all N M1). The project
was approved by the relevant French research commit-
tees (Commission Nationale Informatique et Liberté and
the Comité Consultatif du Traitement Informatique en
Recherche de Santé).
Data and statistical analysis
In the first section, the quality of care is described using
demographic data, tumor characteristics and 27 (11 rec-
tal + 16 colon cancer) care management criteria
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we report medians. In the second section, statistical
models are proposed for 3 specific survival-linked prac-
tices [12,13,15,16]: examination of ≥12 LNs, use of
chemotherapy for stage II patients and non-use for stage
III. Univariate analyses (χ2 or 2-sided Fisher's exact
tests) were performed to identify associations between
these three practice variation factors and the following
factors: age (</≥75 years); location: main residence of
patient (5 administrative districts), place of surgery (per
administrative district) and hospital settings (public or
private); performance status; comorbidities (antecedents
and associated diseases); hospital volume for CRC proce-
dures (</≥ 30 procedures per year); context of operative
procedure (emergency/scheduled) and type of operative
procedure (open, laparoscopy); tumor location; tumor
stage and grade.
Multivariate logistic regression was then used to deter-
mine which variables were significantly and independ-
ently associated with ≥12 LN examination,
chemotherapy use and non-use for stage II and stage III
patients respectively. All statistically significant variables
in the univariate analysis (p< 0.20) were entered simul-
taneously into the full model [17]. We also included po-
tential confounding factors of age, stage and gender for
the LN analyses and gender, age and grade for the two
chemotherapy analyses, regardless of statistical signifi-
cance. Using a manual backwards stepwise selection pro-
cedure, factors with higher p-values were removed until
only variables with a p-value <0.05 were left in the final
model [17]. Moreover, we tested modification effects
adding interaction terms in the final model. None were
statistically significant so they were not included in the
final model. Results are expressed as odds ratios (OR)
with their 95% confidence intervals (95%CI). Analyses
were performed using SPSS Software (version 14.0).
Finally, we used data from the Programme de Medical-
isation des Systèmes d’Information (PMSI) to compare
our cohort to regional data according to setting, and dis-
trict/area, according to numbers of patients and types of
hospitals. Incidences from this regional administrative
hospital and regional medical information system (fur-
ther abbreviated as RMIS) have been validated against
national incidences from the national register (FRAN-
CIM) [18].
Results
Study population and settings
Overall, 1,411 patients were identified for inclusion
across all centers. 205 patients were excluded (27
repeated inclusions, 30 misplaced medical records and
148 ineligible: 44 patients with surgery or multidisciplin-
ary meeting outside of study inclusion; 34 T in situ
(stage 0); 27 patients with relapse; 10 polyp or benigntumors, 6 lymphoma or neuro-endocrine tumors), leav-
ing 1,206 pathologically-confirmed patients: 825 (68%)
with a primary colon cancer and 381 (32%) with a pri-
mary rectal cancer (Table 1). Almost half (42%) of the
cohort was ≥75 years. The majority of patients had one
or more comorbid condition (68% colon, 66% rectal can-
cer). The most common comorbidity was cardiovascular
disease (63% colon, 64% rectal cancer) but a large pro-
portion of patients had an ECOG score 0-1 (66% and
80% for colon and rectal cancer respectively).
Patient care was distributed evenly across public and
private hospitals (50% each), and around one quarter of
patients came from teaching hospitals (1 comprehensive
cancer center and 1 regional university hospital). De-
scriptive data on patients and hospitals from the RMIS
over the same period indicate that our cohort was repre-
sentative in terms of hospital district and setting (Add-
itional file 1: Appendix B). Initial treatment was
delivered in 53 hospitals or clinics with a median of 9.5
study patients per hospital over the one-year study
period (interquartile range: 1.75-30, maximum 110).
Patterns of care: diagnosis, surgery, pathology, adjuvant
treatment and multidisciplinary approach
Considering only scheduled situations (683 colon and
368 rectal cancer patients), colonoscopy was performed
for 91% of colon cancer patients and 87% of rectal can-
cer patients (biopsy for 85% and 96% respectively).
Three hundred and twenty rectal cancer patients (87%)
were locally staged either by a rectal US endoscopy, a
scan or an MRI (following practices at the time). Specif-
ically, 268 received a scan, 15 received MRI and 195
received transrectal US endoscopy, with some patients
receiving more than one examination and a total 54% of
patients receiving either an MRI or a transrectal US en-
doscopy. Concerning the pre-therapeutic work-up, an
abdominal US or computed tomography was performed
in 90% of colon cancer and 94% in rectal cancer
patients.
Resection of the primary tumor (Table 2) was per-
formed in 92% of colon cancer patients (of 825 patients
overall, or 98% of the 767 patients receiving surgery)
and 87% of rectal cancer patients (of 381 patients over-
all, or 97% of the 340 patients receiving surgery). Ab-
dominal perineal resection was performed in 18% of
rectal cancer patients. For patients without preoperative
treatment, median delay between histological diagnosis
and surgery was 17 days in colon cancer patients (532
patients) and 29 days in rectal cancer patients (125
patients).
Eight rectal cancer patients (unknown causes) and 32
colon cancer patients (3 anastomic fistulas, 1 abscess of
the chest wall, 1 pulmonary embolism, 1 pro-lapse, 1 re-
spiratory complication, 1 sub-occlusive syndrome and
Table 1 Colon (n =825) and rectal (n = 381) cancer patient characteristics in the study of surgery and care patterns for
colorectal cancer (n = 1206)
Characteristics Colon Rectal
N (%) N (%)
Median age 72 years – 69 years –
Gender
Men 427 (52) 236 (62)
Women 398 (48) 145 (38)
Comorbid conditions (number)
none 148 (18) 89 (23)
1 238 (29) 105 (28)
2 177 (21) 74 (19)
3 or more 147 (18) 74 (19)
Missing 115 (14) 39 (11)
ECOG Score
0-1 541 (66) 303 (80)
>1 95 (12) 24 (6)
Missing 189 (23) 54 (14)
Family history of disease
Yes 89 (11) 56 (15)
Missing 246 (30) 92 (24)
Colon tumor location
Right 416 (50) –
Left 397 (48) –
Both 12 (2) –
Rectal tumor location
Low – 161 (42)
Median – 129 (34)
High – 91 (24)
Concomitant metastasis 216 (26) 83 (22)
Hospital setting at inclusion
Public 414 (50) 187 (49)
Private 411 (50) 194 (51)
Teaching hospital 178 (22) 123 (32)
Non-teaching hospital 647 (78) 258 (68)
District of surgeon (or oncologist if no surgery)
1 410 (50) 207 (54)
2 151 (18) 73 (19)
3 49 (6) 17 (5)
4 62 (7) 27 (7)
5 147 (18) 52 (14)
Other 6 (1) 5 (1)
Surgical procedures per year
<30 97 (12) 25 (7)
30 and over 659 (80) 312 (82)
Outside area/no surgery 69 (8) 44 (12)
Mathoulin-Pélissier et al. BMC Cancer 2012, 12:297 Page 4 of 10
http://www.biomedcentral.com/1471-2407/12/297
Table 2 Surgical treatment and pathological report for
colon (n= 767) and rectal (n = 340) cancer patients
receiving surgery in the study of surgery and care
patterns for colorectal cancer (n =1107)
Colon Rectal
N (%) N (%)
Mode of operation
Emergency 134 (18) 12 (4)
Scheduled 617 (80) 325 (95)
Missing 16 (2) 3 (1)
Surgical access
Open surgery 651 (85) 245 (72)
Laparoscopy 78 (10) 66 (19)
Transanal 0 – 12 (4)
Missing 38 (5) 17 (5)
Procedures
Colectomy 755 (98) – –
Rectal resection – – 318 (94)
Colostomy alone 12 (2) 10 (3)
Transanal tumorectomy – – 12 (3)
Abdominoperineal resection
Low – – 53 (16)
Mild/high – – 6/1 (2)
Post-operative 30-day mortality 32 (4) 8 (2)
Tumor grade
Well or moderately differentiated 615 (80) 260 (76)
Poorly differentiated 89 (12) 26 (8)
Post-surgical stage
I 82 (11) 85 (25)
II 261 (34) 75 (22)
III 233 (30) 99 (29)
IV 170 (22) 60 (18)
Missing 21 (3) 21 (6)
LNs (number examined)
≥12 575 (76) 209 (66)
≥ 8 673 (89) 273 (86)
Median 17 – 14 –
Margin involvement (R1/(R0+ R1))* 10 (2)} 38† (19)
* n = 490 colon (colostomy alone, R2, RX and missing data excluded); n = 196
rectal (colostomy alone and transanal tumorectomy, R2 and RX excluded).
} : 480 patients R0; 10 R1 (19 R2; 2 Rx and 244 missing data excluded).
† : 158 patients R0; 38 R1 (1 R2 and 119 Rx excluded).
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operatively. Postoperative mortality varied across surgery
setting with 13% mortality (17 patients) in emergency
settings and 2% in scheduled surgeries (15 patients, p
< 0.001). Among surgical complications, clinical anasto-
motic leakage was the main complication, occurring in
5% of colon cancer patients (36 patients) and 10% of rec-
tal cancer patients (26 patients).Incomplete microscopic tumor resection was
described for 2% (10 patients R1) of colon cancer
patients. Circumferential margins for rectal cancer
patients were provided in 65% of pathological reports
(205 patients) and incomplete microscopic tumor resec-
tion was described in 19% of rectal specimens. At least
12 LNs were examined for 70.8% patients overall; 76%
colorectal and 66% rectal.
Among colon cancer patients, adjuvant chemotherapy
was performed in 26% of stage II (66/258 patients) and
71% of stage III (165/231 patients). For all patients, irre-
spective of stage of disease, chemotherapy with LV5FU2
(5-fluoruracil/ folinic acid) was widely used, alone or in
association (stage II: 65/66 patients; stage III: 151/165
patients). Among rectal cancer patients, preoperative
radiotherapy was performed in 84% of stage US T3T4
(177/212 patients), 87% of all N + patients (104/120) and
86% of all stage US T3T4 N+patients (101/117). Post-
operative chemotherapy was administered in 67% of rec-
tal cancer with node-positive US or pathology (92/138
patients).
Finally, a multidisciplinary team approach was taken
before surgery for 14% of colon cancer patients (86/625
patients) and 54% of rectal cancer patients (175/327
patients). For rectal cancer patients, this approach was
used in 67% when a pre-surgical treatment was per-
formed (128/190 patients). After surgery, a multidiscip-
linary team approach was taken for 89% of colon cancer
patients (685/767 patients) and for 80% of rectal cancer
patients (273/340 patients). This results in over 85% of
patients’ cases overall being discussed at some point in
an multidisciplinary meeting.
Variations in process quality measures in colon cancer
patients
ECOG score, tumor localization, district for surgery and
hospital volume were associated with examination of ≥
12 LNs in univariate analyses. After adjustment (Table 3),
the multivariate model showed that patients with ECOG
score 1 (vs. score 0) (OR= 2.10; 95%CI 1.17-3.76), post-
operative stage III (OR= 1.73; 95%CI 1.01-2.95) and
higher hospital volume >30 procedures (OR= 3.34; 95%
CI 1.70-6.56) were more likely to receive examination of
≥12 LNs. Left-sided colon cancer (OR= 0.58; 95%CI
0.34-0.97) and patients undergoing surgery in one of the
five districts (OR= 0.38; 95%CI 0.17-0.85) were nega-
tively associated with examination of ≥12 nodes.
For stage II colon cancer patients, factors associated
with chemotherapy use in the univariate analysis were
younger age, advanced tumor stage, emergency context
for surgery, and private hospital setting. In the multivari-
ate analysis, the use of chemotherapy was associated
with age <75 years (OR= 28.49; 95%CI 8.41-96.53),
advanced tumor stage i.e. pT4 (OR= 12.30; 95%CI 3.81-
Table 3 Factors associated with LN evaluation (LNE) or use of adjuvant chemotherapy (ACT) in colon cancer practices:
uni- and multi-variate models
Univariate Multivariate
OR [95%CI] p OR [95%CI] p
Evaluation of≥ 12 LNs* 581 pts 399 pts
ECOG score 0.011 0.014
0 1 ref 1 ref
1 2.02 [1.20-3.41] 2.10 [1.17-3.76]
2 and more 0.81 [0.41-1.60] 0.72 [0.33-1.55]
Tumor location 0.003 0.036
Right 1 ref 1
Left 0.54 [0.36-0.81] 0.58 [0.34-0.97]
Post-operative stage 0.525 0.044
I -II 1 ref 1 ref
III 1.14 [0.76-1.72] 1.73 [1.01-2.95]
Hospital surgery volume 0.001 <0.001
< 30 operations 1 ref 1 ref
≥ 30 operations 2.48 [1.46-4.21] 3.34 [1.70-6.56]
Surgical district <0.001 0.006
1 1 ref 1.00 ref
2 1.62 [0.90-2.91] 2.07 [0.97-4.42]
3 1.10 [0.48-2.51] 1.30 [0.35-4.88]
4 0.34 [0.18-0.64] 0.38 [0.17-0.85]
5 1.32 [0.73-2.40] 1.54 [0.84-3.40]
Receiving ACT among stage II† 258 pts 255 pts
Age (years) <0.001 <0.0011
≥75 1 ref 1 ref
< 75 8.68 [4.06-18.54] 28.49 [8.41-96.53]
Local extension <0.001 <0.001
pT3 1 ref 1 ref
pT4 4.07 [2.12-7.81] 12.30 [3.81-39.75]
Surgery context <0.001 <0.001
Scheduled 1 ref 1 ref
Emergency 6.89 [3.21-14.73] 25.31 [6.79-94.34]
Hospital of surgery 0.009 0.020
Public 1 ref 1 ref
Private 2.18 [1.21-3.95] 2.61 [1.16-5.87]
Surgical district 0.090 0.036
1 1 ref 1 ref
2 0.53 [0.25-1.13] 0.54 [0.19-1.53]
3 1.89 [0.54-6.56] 1.45 [0.31-6.75]
4 0.28 [0.06-1.29] 0.06 [0.08-0.39]
5 0.57 [0.25-1.29] 0.44 [0.14-1.44]
Not receiving ACT among stage III† 231 pts 226 pts
Age (years) <0.001 <0.001
< 75 1 ref 1 ref
≥75 8.80 [4.51-17.17] 8.83 [4.34-17.95]
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Table 3 Factors associated with LN evaluation (LNE) or use of adjuvant chemotherapy (ACT) in colon cancer practices:
uni- and multi-variate models (Continued)
Comorbid conditions 0.001 0.010
None 1 ref 1 ref
One or more 3.46 [1.65-7.27] 3.04 [1.31-7.04]
Hospitals 0.024 0.285
Private 1 ref 1 ref
Public 1.94 [1.09-3.45] 1.48 [0.72-3.03]
* Logistic model was adjusted by gender and age. Factors entered into the model but not retained are: department of patient residence, pre-operative
colonoscopy, pre-operative abdominal ultrasound, usN, grade, type of colectomy. †ACT stage II and III: Logistic model was adjusted by gender and grade. Factors
entered into the model but not retained for stage II patients: department of patient residence, comorbidities, family history of colorectal cancer; for stage III:
family history of colorectal cancer and surgical district.
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94.34) and private surgical hospitals (OR= 2.61; 95%CI
1.16-5.87). Adjuvant chemotherapy use was less likely in
one of the five districts (OR= 0.06; 95%CI 0.08-0.39).
For stage III colon cancer patients, adjuvant chemo-
therapy was used for 89% of 134 patients< 75 years and
for 47% of 97 patients ≥75 years (p< 0.001). Older age,
presence of comorbidities and public hospitals were
associated with the non-use (under-use) of adjuvant
chemotherapy for stage III patients. The age effect and
presence of comorbidities remained significant after
multivariate analysis (OR= 8.83;95%CI 4.34-17.95; OR=
3.04, 95%CI 1.31-7.04 respectively).
Discussion
This is the most recent study to report on patterns of
colorectal cancer care in this French region. The major-
ity of CRC patients were 70 years or older and most
were treated in non-teaching hospitals. Overall, adher-
ence to recommendations was good, but varied across
hospitals and districts. For some important steps of can-
cer care (resection, pathology report, LN examination,
chemotherapy in stage III, rectal radiotherapy), adher-
ence was the same or higher than in other studies
[19,20]. Over 70% of patients received standard care with
chemotherapy for stage III colon cancer, although the
proportion was lower for older patients. For rectal can-
cer patients, a majority (62%) of patients received pre-
operative radiotherapy which may reflect more frequent
pre-operative use in Europe than in the United States
where rates are reportedly on the rise [21]. Moreover,
these results across an entire region in the year following
guideline implementation show good adherence to the
approach directly after. The main factors of non-
compliance with recommendations were the high use of
chemotherapy in stage II colon cancer and the under-
use of diagnostic assessment for rectal cancer.
The examination of ≥12 LNs was associated with five
factors: ECOG score, tumor characteristics (location and
stage) and hospital characteristics (administrative district
and volume of CRC procedures). These factors wereconcordant with almost all results published to date
[12,22,23]. Pathological findings concerning resection
specimens showed that for most CRC cases ≥12 LNs
were examined, yet the proportion was slightly lower
among rectal cancer patients compared to colon cancer
patients. Radiotherapy before surgery may explain the
lower proportion in rectal cancer patients due to
reduced lymph node harvests post-radiotherapy [24,25].
Numerous studies and consensus guidelines have sug-
gested that the 12 LN threshold is a reasonable mini-
mum for adequate nodal evaluation in colon cancer,
however there is still some uncertainty regarding the im-
pact on survival [13,26,27].
To explain the under-use of chemotherapy in stage III,
our study analyzed factors related to the potential risks of
chemotherapy, finding very low use for patients over
75 years as has been reported in a similar population-based
study [28]. While the efficacy of adjuvant therapy for stage
III colon cancer was emphasized in the 1990s, age and
comorbidity have always played a role in the decision to use
adjuvant therapy in stage III [29], and it is mostly offered to
healthy patients under 75 years old with recent results sup-
porting the under-use for elderly patients [14,30].
Conversely, we chose to explain the determinants for
using chemotherapy in stage II since at the time of
study, adjuvant chemotherapy was generally not indi-
cated in these cases. For stage II colon cancer, the
present results show that in 2003-2004, younger age,
advanced stage, emergency setting and healthcare
organization (districts or sector hospitals) were asso-
ciated with the use of chemotherapy. These results are
in accordance with previous work showing that younger
age, advanced stage, emergency presentation and discus-
sion in multidisciplinary meetings were associated with
adjuvant chemotherapy use for stage II patients [14]. At
the time of this study, the national recommendations
were not clear in terms of management options for stage
II patients but these have since be clarified and adjuvant
chemotherapy use appears to be indicated for specific
stage II patients [31], although this still remains to be
confirmed [32].
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surgery seems smaller in magnitude than that in other di-
gestive procedures, consideration must be given as to
whether regionalization of CRC care is an appropriate
mechanism for quality improvement [33]. In our study, we
confirmed the importance of district as a source of hetero-
geneity in cancer colorectal management [4-6] This infor-
mation could be a confounding factor with the hospital
volume procedure, but we took this into account in our
multivariate analysis and found an effect for both hospital
district and volume. The hospital volume effect on examin-
ation of ≥12 LNs has been emphasized recently [23,34].
Our findings should be interpreted in the light of sev-
eral limitations. First, our colorectal cohort was not ex-
haustive since the estimation of CRC incidence in this
area was over 2000 new patients. However, similar pa-
tient and hospital characteristics were found in studies
using data from French cancer registries or regional
medical information systems [35,36]. A second limita-
tion is our study size which is smaller than similar stud-
ies [22,23,37]. This lower power would explain why we
did not identify stage as independent factors for LN
examination. In addition, we had no information regard-
ing patients’ socio-economic status [38] or treatment
choice; two factors known to be relevant when explain-
ing differences in care management. We also collected
comorbidity information by using patients’ medical
records, a method somewhat insufficient to capture the
range and severity of the comorbidity.
In terms of interpreting whether the results reported
here specifically reflect improvements after implementa-
tion of guidelines, with this observational design we can-
not infer a definite causality link, although all efforts
were undertaken to widely and comprehensively distrib-
ute guidelines as described in the methods. To provide
an indication of trends in practices across time in
France, we collated information from four comparable
studies performed between 1900 and 2004 [4,14,36,39].
We note that the general trend for chemotherapy use in
stage II patients did not change between 1990-1999
(21.8%) [4] to 2000 (20.4%) [14] and 2003/2004 (20.6%)
in the present study. For stage III patients, the trend is
towards an increase in the use of chemotherapy with
usage reported at 47% in 1990-1999 [4], 61% in 2000
[14] and 71% in our study. Discussion in multidisciplin-
ary meetings also appears to be on the rise. In 2000, be-
tween 32% [36] and 61% [14] of patients’ files were
discussed in multidisciplinary meetings, compared to
>85% in our series on the whole. Local population-
based cancer registry data (unpublished data, http://
www.registres-cancers-aquitaine.fr/) indicate that in one
administrative district included in this region, discussion
in multidisciplinary meetings for colorectal cancer
patients increased from 48% to 63% between 2005 and2008. We expect that with the creation of the National
Institute for Cancer (INCa) in 2005 and standardized na-
tional guidelines, this trend is probably robust and con-
tinuous. Finally, trends in inspection of ≥12 LNs appear
to be increasing with 45.2% compliance in 1997-2004
[40] compared to 70.8% in our study.
A final limitation is the differences in practices that
may have occurred between time of observation and this
publication, for example with magnetic resonance im-
aging practices. However, these data provide a validated
measure of colorectal cancer care that may be applied in
other regions and countries. The three NCCN quality
indicators [11] examined here are supported as good
measures of identifying practice variation that may be
linked to survival differences.Conclusions
These findings show that there is a need to clarify
underlying differences in practices observed not only on
the basis of patients or tumor-related characteristics but
also other factors, particularly hospital factors such as lo-
cation and volume [41]. This is essential before comparing
survival in CRC patients. Potential mechanisms underlying
the relationships between volume and survival after colo-
rectal surgery do not seem to have been characterized [42].
It is important to remember that many hospital-related fac-
tors, such as types of services, multidisciplinary teams and
internal quality programs potentially explain differences in
care management and cancer survival [43,44]. However, in
2009, the French cancer plan implemented a system au-
thorizing cancer care only in hospitals above a specific vol-
ume threshold. For example, in digestive cancer surgery,
the minimum number of cancer procedures is set at 30 per
year [45], under which digestive cancer surgery is not
authorized.
Overall, these data provide indication that adherence to
clinical practice guidelines was relatively good in the year
following their implementation by a multidisciplinary
group. Since this date, the regional groups have estab-
lished a quality of cancer care program for CRC in 2008
and new guidelines have been implemented, particularly
for LN evaluation or the use of chemotherapy in certain
stage II patients. A further study is underway using these
updated criteria to further document practices in colorec-
tal cancer care and report on survival (EvaCCoR).
In conclusion, this study provides good insight into
real clinical practices (effectiveness) for a given popula-
tion of patients treated in a designated geographical
area when an experimental design is either not feasible
or too complex to implement and hospital cohorts are
not recommended. This point is particularly important
for CRC because many patients are treated outside
teaching hospitals.
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